Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 1,169.5	$ 2,326.5
Marketable securities	1,723.5	2,568.6
Accounts receivable, net	1,630.2	1,441.6
Due from anti-CD20 therapeutic programs	502.9	300.6
Inventory	936.5	1,001.6
Other current assets	1,146.1	1,093.3
Total current assets	7,108.7	8,732.2
Marketable securities	2,632.7	2,829.4
Property, plant and equipment, net	2,827.6	2,501.8
Intangible assets, net	4,051.3	3,808.3
Goodwill	3,870.4	3,669.3
Investments and other assets	1,268.3	1,335.8
Total assets	21,759.0	22,876.8
Current liabilities:
Current portion of notes payable and other financing arrangements	559.9	4.7
Taxes payable	52.6	231.9
Accounts payable	330.3	279.8
Accrued expenses and other	2,436.9	2,903.5
Total current liabilities	3,379.7	3,419.9
Notes payable and other financing arrangements	5,954.0	6,512.7
Deferred tax liability	100.8	93.1
Other long-term liabilities	750.9	722.5
Total liabilities	10,185.4	10,748.2
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	19.3	0.0
Accumulated other comprehensive loss	(338.8)	(319.9)
Retained earnings	14,881.7	15,071.6
Treasury stock, at cost	(2,977.1)	(2,611.7)
Total Biogen Inc. shareholders’ equity	11,585.2	12,140.1
Noncontrolling interests	(11.6)	(11.5)
Total equity	11,573.6	12,128.6
Total liabilities and equity	$ 21,759.0	$ 22,876.8